Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10523780 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTMMP8TSHRMEN1 | |
| SCHEMBL9530414 | 0.89 | SMN1; SMN2 (0.48) | SMN1; SMN2MAPTMMP8TDP1LMNA | |
| SCHEMBL1421006 | 0.86 | SMN1; SMN2 (0.58) | SMN1; SMN2MAPTTSHRMEN1KMT2A | |
| SCHEMBL3507308 | 0.85 | TSHR (0.50) | SMN1; SMN2MAPTTSHRMEN1KMT2A | |
| SCHEMBL27492502 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPTMMP8TSHRMEN1 | |
| SCHEMBL7437317 | 0.85 | ALDH1A1 (0.50) | SMN1; SMN2TSHRKMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7265343 | 0.84 | TSHR (0.54) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL2340596 | 0.83 | MMP8 (0.58) | SMN1; SMN2MAPTMMP8TSHRMEN1 | |
| SCHEMBL18065697 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPTMMP8TSHRMEN1 | |
| SCHEMBL935980 | 0.83 | TDP1 (0.59) | SMN1; SMN2MAPTMMP8TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1121297-A | — | — | None | — | — | JP | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| CN-102964239-B | metal-beta-lactamase inhibitor | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| CN-101267815-B | metallo-beta-lactamase inhibitors | MEIJI SEIKA PHARMA CO LTD | 2013-11-06 | — | — | CN | disclosed |
| CN-102964239-A | Metallo-beta-lactamase inhibitor | MEIJI SEIKA KAISHA | 2013-03-13 | — | — | CN | disclosed |
| US-8143263-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | CHIKAUCHI KEN (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8093294-B2 | Bacterial infections; effective for recovering the activities of beta-lactam antibiotics; 2-ethyl-3-methylmaleic acid dimethyl ester; maleic acid derivatives and/or dihydrofuranyl derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| EP-2324028-A2 | THERAPEUTIC AGENTS 414 | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-0096157-A2 | Substituted acyl derivatives of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid | WARNER-LAMBERT COMPANY (US) | 1983-12-21 | — | — | EP | disclosed |
| EP-0095163-A2 | 2-Oxo-imidazolidine compounds, a process for preparing the same and a pharmaceutical composition | Tanabe Seiyaku Co., Ltd. (JP) | 1983-11-30 | — | — | EP | disclosed |
| US-4410520-A | ANGIOTENSION CONVERTING ENZYME INGIBITOR, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0088350-A1 | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them | SCHERING CORPORATION (US) | 1983-09-14 | — | — | EP | disclosed |
| EP-0088342-A1 | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| EP-0088341-A1 | Substituted acyl derivative of octahydro-1H-indole-2-carboxylic acid | WARNER-LAMBERT COMPANY (US) | 1983-09-14 | — | — | EP | disclosed |
| US-4350704-A | HYPOTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1982-09-21 | — | — | US | disclosed |
| US-4344949-A | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1982-08-17 | — | — | US | disclosed |
| EP-0049605-A1 | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids, salts thereof, pharmaceutical compositions containing the derivatives or salts, and the production of the same | WARNER-LAMBERT COMPANY (US) | 1982-04-14 | — | — | EP | disclosed |
| EP-0037231-A2 | Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids | WARNER-LAMBERT COMPANY (US) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071457-A1 | METALLO-BETA-LACTAMASE INHIBITORS | ME1, MGAM, GAA | SMN1; SMN2 2666/4885MAPT 2687/4885MMP8 177/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | SMN1; SMN2 2687/4885MAPT 2972/4885MMP8 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.